First of all, I hope friends understand the basic concept of stage III (T3N0M0) prostate cancer: the tumor is still confined to the prostate or has invaded the seminal vesicles or prostate envelope, but local lymph node metastasis has not been detected or confirmed. In the classification of prognostic risk factors for prostate cancer, most of them belong to intermediate or advanced risk level. Today, there are three issues of stage III prostate cancer that are of great clinical concern at home and abroad. (1) It is recognized at home and abroad that stage III prostate cancer is potentially curable. In short, if the approach is reasonable and appropriate, patients may be able to obtain early (stage II) treatment results. If it is easy for friends to understand, it can be described as a “tug of war”. (2) Currently, which is the better choice among surgery, external radiotherapy, brachytherapy (radioactive particle implantation), argon helium cryoablation, and/or pharmacological endocrine therapy? It is controversial because of the lack of evidence-based medical evidence and no uniform opinion or standard has been formed. (3) The prognosis of stage III prostate cancer is moderate to high risk patients, therefore, the ease of recurrence and progression after treatment is a difficult problem in the field of treatment both at home and abroad. The treatment targets are those at high risk of clinical progression including local recurrence, so diverse and comprehensive treatment is needed, but there are technical and strategic issues. Patients should understand that the treatment of stage III prostate cancer is still in the exploratory stage at home and abroad, therefore, it is not yet possible to evaluate which treatment is good or bad. However, based on our long-term clinical practice and our knowledge and summary of stage III prostate cancer, based on our latest set of clinical research results (see the article in Academic Update) and the latest foreign literature, we suggest the following for your reference in treatment selection only. 1. Preferred treatment methods and combined treatment issues (1) Radical surgery is preferred. After surgery, we should wait for observation and implement radiotherapy if there is local recurrence; or elective radiotherapy after surgery; combined with drug endocrine therapy. (2) Cryotherapy is preferred (for those who are not suitable for surgery and want minimally invasive treatment). Postoperatively, wait for observation, and then administer radiotherapy if there is local recurrence; or elective postoperative radiotherapy. (3) Prefer radiotherapy. If there is local recurrence, salvage cryotherapy is used; combined with drug endocrine therapy 2. Adjuvant drug endocrine therapy problem Also known as hormone blocking method, it has replaced surgical testicular denervation surgery abroad and is one of the important comprehensive treatment methods, but conversion to hormone non-dependent (treatment failure) within a certain period of time is almost inevitable. In order to delay the occurrence of non-dependent adverse events, intermittent (interval time) and crossover (alternating first, second and third line drugs) administration has been mostly advocated in recent years. According to our latest study, only 11.1% (5/45) of patients required pharmacological endocrine therapy within 10-45 months after the use of single cryotherapy. Therefore, we believe that it is reasonable, effective, and feasible to reserve the space for treatment until clinical progress is confirmed and then give pharmacological therapy, provided that the treatment is effective. It is reasonable, effective and feasible. The latest foreign research results also support our view. Of course, the T3b stage should be combined with pharmacological endocrine therapy As the saying goes, there is no fear of burning firewood when you stay in the green hills. As the saying goes, the continuous crossover, penetration and integration of medical science and modern high technology will certainly give rise to new treatment technologies and methods and enrich the relevant treatment content. So, if you wait, you have a chance.